Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Biotech Histochem. 2013 Aug 1;88(7):410–424. doi: 10.3109/10520295.2013.807069

Table 4.

Examples of miRNAs expressed differentially in metastatic prostate cancer and also identified by other studies (based primarily on Volinia et al. 2006, Porkka et al. 2007, Tong et al. 2009, Szczyrba et al. 2010, Watahiki et al. 2011, Carlsson et al. 2011)

MiRNA Down-regulated in metastatic cell line (fold change if specified) Previously reported to be differentially expressed in prostate cancer compared to benign prostatic tissue (fold change if specified) Previously identified as modulating metastasis of prostate cancer Previously reported as affecting metastasis in a different cancer (e.g., breast cancer)
miRNA-16 (−20) Down-regulated2 Yes Yes
miRNA-24 (−8) (−1.5) Yes
miRNA-29a (−30) (−2)
miRNA-34a (−3) Down-regulated2 Yes Yes
miRNA-126* (−3) Down-regulated2
miRNA-145 (−3) (−4) Yes Yes
miRNA-195 (−5) Down-regulated2
miRNA-203 (−1.5) Down-regulated2 Yes Yes
miRNA-205 (NA)1 Down-regulated2 Yes Yes
miRNA-221 Down-regulated2 (−1.3)(−2) Yes* **
miRNA-425 (−6) Down-regulated2
miRNA Up-regulated in metastatic cell line (fold change if specified) Previously reported to be differentially expressed in prostate cancer compared to benign prostatic tissue (fold change if specified) Previously identified as modulating metastasis of prostate cancer Previously reported as affecting metastasis in a different cancer (e.g., breast cancer)
Let7i (2) Up-regulated2 Yes
miRNA-21 (1.7) Variable reports Yes
miRNA-106a (3.3) (2.8) Yes
1

Cannot be calculated because it was not detectible in metastatic tumors

2

Extent of differences in expression

*

Correlated with TMPRESS2:ERG fusion (Gordanpour et al. 2011)

**

Up-regulated in aggressive breast cancer and hepatocellular carcinoma (Shah and Calin 2011, Fu et al. 2010)